Sofosbuvir is a nucleotide analog polymerase inhibitor, the first FDA-approved all-oral treatment for patients with HCV genotypes 2 or 3.
The drug received approval shortly after simpeprevir, an Olysio, Janssen Therapeutics drug for patients with HCV genotype 1.
Sofosbuvir is a product of Gilead Sciences.
More Articles on Gastroenterology:
5 Current Treatments for Ulcerative Colitis
New Test Offers Promise of Simpler Celiac Disease Diagnosis
5 Things to Know About Advances in Oral Treatment for Hepatitis C
